ARV-471: an ER-targeting protein degrader for breast cancer
Arvinas is developing ARV-471, an oral estrogen receptor (ER)-targeting PROTAC® protein degrader for the potential treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. Arvinas and Pfizer have a global collaboration to co-develop and co-commercialize ARV-471.
This program is currently in a Phase 2 clinical study.
Breast Cancer
80% of newly diagnosed cases of breast cancer are ER+
Approximately 80% of all newly diagnosed cases of breast cancer are ER alpha-positive (ER+). While approved treatments have produced some success in this patient population, many ER+ breast cancers become resistant to therapy. Today, fulvestrant (Faslodex®)—a selective estrogen receptor degrader (SERD)—is the standard of care for ER+ metastatic breast cancer after anti-estrogen therapy. While fulvestrant has validated the importance of ER degradation as a therapeutic intervention, up to 50% of ER can remain when compared to baseline levels after six months of treatment with fulvestrant. Unlike fulvestrant, which is administered via intramuscular injection, Arvinas’ ER-directed PROTAC protein degrader, ARV-471, is an oral therapy under development for the treatment of women with ER+ metastatic breast cancer.
Preclinical studies
In preclinical studies ARV-471 has shown promising activity as an ER degrader, demonstrating superior tumor growth inhibition compared to fulvestrant. ARV-471 has demonstrated potency as both a single agent and as a combination therapy with CDK4/6 inhibitors.
Select in vivo data
In a patient-derived xenograft (PDX) model from an ESR1 mutant patient, an oral dose of ARV-471 inhibited tumor growth by 99% at 10 milligrams per kilogram (mpk) and 106% at 30 mpk (below). This suggests ARV-471’s potential as a superior inhibitor of tumor growth compared to fulvestrant.
CDK4/6 inhibitors, such as palbociclib (Ibrance®), are often used in combination with fulvestrant. In the study shown, comparing ARV-471 in combination with palbociclib versus fulvestrant in combination with palbociclib, ARV-471/palbociclib demonstrated superior tumor shrinkage (tumor growth inhibition: 131%) in comparison to fulvestrant/palbociclib (tumor growth inhibition: 108%).
Arvinas is currently evaluating ARV-471 in a Phase 1 study for patients with locally advanced or metastatic ER+ positive / HER2- negative breast cancer. In future studies, Arvinas intends to study ARV-471 as both a single agent and in combination with other therapies, such as CDK4/6 inhibitors.
This website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our Privacy Policy.